ArticleAnnals of the rheumatic diseases2020
To immunosuppress: whom, when and how? That is the question with COVID-19.
Article in Annals of the rheumatic diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Trial
- Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19.European journal of hospital pharmacy : science and practice · 2022Observational
- Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.Rheumatology international · 2021Observational
- COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.Journal of Korean medical science · 2021Review
- COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions.RMD open · 2021Article
- COVID-19 pandemic management and the rheumatology patient.Best practice & research. Clinical rheumatology · 2021Review
- [COVID-19: Still a place for tocilizumab?]La Revue de medecine interne · 2021Review
- COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases.Frontiers in immunologyReview
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.